Tumors relapsing from antiangiogenic therapy did not only convert myeloid cells into a Th2 state, but they also enhanced the levels of the negative immune checkpoint regulator PD-L1 in tumor and stromal cells (116, 117). This evidence concerns the gene CD274 and neoplasm.